Alexion's Soliris misses mark in Phase III MG trial

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) sank $16.02 (10%) to $138.97 in early after-hours trading after it said Soliris eculizumab missed the primary endpoint of the Phase

Read the full 259 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE